West Pharmaceutical Services, Inc. (WST) Earnings Call Transcripts

West Pharmaceutical Services, Inc.'s Latest Earnings Call - Q3 FY2026

In Q3 2026, West Pharmaceutical Services reported strong financial results, with revenues of $874 million, reflecting a 12% organic growth, and adjusted EPS of $2.66, up 36% year-over-year. Management raised full-year revenue guidance to a range of $3.41 billion to $3.42 billion, up from a prior range of $3.345 billion to $3.38 billion, indicating robust performance across segments. The company also highlighted significant growth in its Proprietary Products segment, particularly in HVP components, which grew 20% organically, driven by demand for GLP-1 products and upgrades.

Reported metrics

Guidance from management

Management raised full-year adjusted EPS guidance to a range of $9.38 to $9.48, up from a prior range of $8.85 to $9.05, indicating strong earnings momentum.

What management said

Thank you, Bob. So early days for me, I'm incredibly excited about the journey ahead. This year, we're on track to deliver over 40 billion highly critical components to our customers. This gives you a good sense of the dimensions of the patient impact our colleagues are focused on delivering. And this is why West is such an incredible company with a great financial profile that allows us to compound EPS consistently ...

Yes. Maybe I can start just generally, obviously, small base. And so we're excited about the growth as that market continues to provide as with lots of new customer opportunities. And so I would say a great contributor to growth this quarter.

What analysts pressed on

Analysts expressed concerns about the sustainability of growth in the GLP-1 market and the impact of regulatory changes on future performance. There were also questions regarding the potential for elevated CapEx spending in the coming years.

Main topics on the call

• Revenue Growth Acceleration — West's Q3 revenues reached $874 million, growing 12% organically. CEO Michel Lagarde noted, "I'm pleased to report that we've had a great third quarter, exceeding our expectations for both revenues and earnings."
• Segment Performance — The Proprietary Products segment delivered 16.6% organic growth, with HVP components growing 20%. CFO Bob McMahon stated, "The performance was broad-based and driven by multiple factors, including robust growth in biolog...
• Guidance Update — Management raised full-year revenue guidance to $3.41 billion to $3.42 billion, up from $3.345 billion to $3.38 billion. Bob McMahon indicated, "This revised guidance assumes full year 2026 organic sales growth of 11.3% ...
• Margin Expansion — Total company gross margin improved to 39.7%, up 310 basis points year-over-year. McMahon noted, "The year-on-year increase was primarily driven by better-than-expected proprietary product sales and the associated positi...

Read the full West Pharmaceutical Services, Inc. transcript (Q3 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 80 West Pharmaceutical Services, Inc. earnings call transcripts on record, spanning January 16, 2020 to October 29, 2026. Based on this history, West Pharmaceutical Services, Inc. reports quarterly. The most recent call on file is dated October 29, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

WST

Exchange

NYSE

Country

US

Sector

Health Care

Industry

Life Sciences Tools and Services

Calls on record

80

First call

January 16, 2020

Most recent

October 29, 2026

Reporting cadence

quarterly